Evidence map›Paper›PMID 34277994›Full record

ArticleEndocrinology, diabetes & metabolism2021

The AGE receptor, OST48 drives podocyte foot process effacement and basement membrane expansion (alters structural composition).

Aowen Zhuang, Felicia Y T Yap, Danielle J Borg, Domenica McCarthy, Amelia Fotheringham, Sherman Leung, Sally A Penfold, Karly C Sourris, Melinda T Coughlan, Benjamin L Schulz and 1 more

Open access · goldAbstract read
In one paragraph

Article in Endocrinology, diabetes & metabolism, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. The Gut-Kidney Axis in Chronic Kidney Diseases.Diagnostics (Basel, Switzerland) · 2024
    Review
  3. A Role for Advanced Glycation End Products in Molecular Ageing.International journal of molecular sciences · 2023
    Review
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Aowen ZhuangGlycation and Diabetes Complications Mater Research Institute - The University of Queensland Translational Research Institute Woolloongabba Qld Australia.ORCID 0000-0002-7409-6629
Felicia Y T YapBaker Heart and Diabetes Institute Melbourne Vic Australia.
Danielle J BorgGlycation and Diabetes Complications Mater Research Institute - The University of Queensland Translational Research Institute Woolloongabba Qld Australia.ORCID 0000-0001-6126-7583
Domenica McCarthyGlycation and Diabetes Complications Mater Research Institute - The University of Queensland Translational Research Institute Woolloongabba Qld Australia.
Amelia FotheringhamGlycation and Diabetes Complications Mater Research Institute - The University of Queensland Translational Research Institute Woolloongabba Qld Australia.
Sherman LeungGlycation and Diabetes Complications Mater Research Institute - The University of Queensland Translational Research Institute Woolloongabba Qld Australia.
Sally A PenfoldBaker Heart and Diabetes Institute Melbourne Vic Australia.
Karly C SourrisBaker Heart and Diabetes Institute Melbourne Vic Australia.
Melinda T CoughlanBaker Heart and Diabetes Institute Melbourne Vic Australia.
Benjamin L SchulzSchool of Chemistry and Molecular Biosciences University of Queensland St Lucia Qld Australia.
Josephine M ForbesGlycation and Diabetes Complications Mater Research Institute - The University of Queensland Translational Research Institute Woolloongabba Qld Australia.ORCID 0000-0002-5595-8174
Translational Research Institute · AUBaker Heart and Diabetes Institute · AUThe University of Queensland · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThe accumulation of advanced glycation end products is implicated in the development and progression of diabetic kidney disease. No study has examined whether stimulating advanced glycation clearance via receptor manipulation is reno-protective in diabetes. Podocytes, which are early contributors to diabetic kidney disease and could be a target for reno-protection. MATERIALS AND

methodsTo examine the effects of increased podocyte oligosaccharyltransferase-48 on kidney function, glomerular sclerosis, tubulointerstitial fibrosis and proteome (PXD011434), we generated a mouse with increased oligosaccharyltransferase-48kDa subunit abundance in podocytes driven by the podocin promoter.

resultsDespite increased urinary clearance of advanced glycation end products, we observed a decline in renal function, significant glomerular damage including glomerulosclerosis, collagen IV deposition, glomerular basement membrane thickening and foot process effacement and tubulointerstitial fibrosis. Analysis of isolated glomeruli identified enrichment in proteins associated with collagen deposition, endoplasmic reticulum stress and oxidative stress. Ultra-resolution microscopy of podocytes revealed denudation of foot processes where there was co-localization of oligosaccharyltransferase-48kDa subunit and advanced glycation end-products.

conclusionsThese studies indicate that increased podocyte expression of oligosaccharyltransferase-48 kDa subunit results in glomerular endoplasmic reticulum stress and a decline in kidney function.

Indexed as

Diabetic NephropathiesPodocytesAnimalsGlomerular Basement MembraneGlycation End Products, AdvancedMiceReceptor for Advanced Glycation End ProductsGlycation End Products, AdvancedReceptor for Advanced Glycation End Productsadvanced glycation end‐product receptor 1advanced glycation end‐productsdiabetesdiabetic kidney diseaseendoplasmic reticulum stressoligosaccharyltransferase‐48 diabetic nephropathy

Identifiers

PMID34277994
PMCPMC8279619
OpenAlexW3175389098

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.